ERT Virtual Trials COVID-19 Survey Report
With the onset of the COVID-19 pandemic, clinical trial sponsor companies and CROs hastened to implement virtual trial technologies. The virtual visits and digital data exchange would enable them to start or continue studies, despite government mandates requiring patients and staff to stay at home.
During the COVID-19 lockdown, in April and May 2020, ERT surveyed clinical professionals on how the demands of the pandemic were affecting their organizations’ use and planned use of virtual trial technologies. Download the free eBook, Virtual Trials and the COVID-19 Pandemic: The State of Clinical Trials, to learn about their responses and industry trends.
Key takeaways from the report include:
- Organizations will increasingly run full or hybrid virtual clinical trials moving forward because of associated improvements in patient engagement, timeframes, cost effectiveness and data fidelity.
- 82% of clinical trial professionals polled stated that their organizations are incorporating elements of virtual clinical trials due to the pandemic.
- The biggest issue keeping participants up at night is screening for new clinical trials patients (79%)
- The most common ways to collect data in a virtual clinical trial are telehealth (75%) and patient-used devices (75%)
- The primary issues impacting trials over the next six to twelve months are trial management (32%) and patient recruitment and enrollment (25%)
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
America’s Vanishing Scientific Research Workforce is a Threat to Public Health
June 2nd 2025As biotech innovation accelerates, the clinical research workforce is rapidly eroding—threatening the future of drug development. From workforce burnout to training program cuts and talent pipeline collapse, clinical trial professionals must confront this escalating crisis head-on to sustain progress and protect public health.
Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond
